|
BP10628
|
NS-1619
|
|
|
|
|
NS1619 have cardio-protective effects after ischemia-reperfusion injury.
|
|
BP10853
|
NS309
|
|
|
|
|
NS309 is a nonselective activator of small- and intermediate-conductance Ca2+-activated K+ (SK/KCa2 and IK/KCa3.1) channels (EC50s range from 0.12-1.2 μM for SK channels and 10-90 nM for IK channels). It can also activate voltage-gated Kv11.1 channels (hERG; IC50 = 1 μM), but does not, however, affect large conductance (BK/KCa1.1) channels. NS309 can modulate neuronal firing patterns by enhancing SK-mediated hyperpolarizing effects. It is 730-fold (SK channels) and 7,400-fold (IK channels) more potent than 1-EBIO and often used in conjunction with CyPPA to distinguish between SK1 and SK3 subtypes.
|
|
BP10158
|
NSC 228155
|
|
|
|
|
NSC228155 is an activator of EGFR, binding to the sEGFR dimerization domain II and modulate EGFR tyrosine phosphorylation.
|
|
BP10197
|
NSC 23766 trihydrochloride
|
|
|
|
|
NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by GEFs (IC50: ~50 μM); no inhibitory for the closely related targets, RhoA or Cdc42.
|
|
BP10901
|
NSC 42834
|
|
|
|
|
NSC 42834(JAK2 Inhibitor V, Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.
|
|
BP10638
|
NU 7026
|
|
|
|
|
NU7026 is an effective DNA-PK inhibitor (IC50: 0.23 μM, in cell-free assays), 60-fold selective for DNA-PK than PI3K and no inhibition against both ATM and ATR.
|
|
BP10322
|
NVP-2
|
|
|
|
|
NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50: 0.514 nM). NVP-2 shows inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases (IC50: 0.584 μM, 0.706 μM, and 0.605 μM, respectively).
|
|
BP10121
|
NVP-BSK805
|
|
|
|
|
NVP-BSK805 is an ATP-competitive JAK2 inhibitor.
|
|
BP10888
|
NVP-BSK805 dihydrochloride
|
|
|
|
|
NVP-BSK805 dihydrochloride is an effective and selective inhibitor of JAK2 with IC50s of 0.5 nM, 10.76 nM, 18.68 nM, and 31.63 nM for JAK2, TYK2, JAK3, and JAK1.
|
|
BP10362
|
NVP-CGM097
|
|
|
|
|
NVP-CGM097 is an effective and specific MDM2 inhibitor (IC50: 1.7 nM for hMDM2).
|
|
BP10488
|
NVP-TNKS656
|
|
|
|
|
NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor.
|
|
BP10468
|
Nystatin
|
|
|
|
|
Nystatin is a topical and oral antifungal agent with activity against many species of yeast and candida albicans, which is used largely to treat skin and oropharyngeal candidiasis.
|
|
BP10918
|
O6-Benzylguanine
|
|
|
|
|
O6-Benzylguanine is a guanine analog with antineoplastic activity,and is a potent O6-alkylguanine DNA alkyltransferase (AGT) inactivator.
|
|
BP10708
|
Oclacitinib maleate
|
|
|
|
|
Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases.
|
|
BP10526
|
ODM-203
|
|
|
|
|
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
|
|
BP10082
|
Oenothein B
|
|
|
|
|
Oenothein B is a specific inhibitor of poly(ADP-ribose) glycohydrolase. Oenothein B shows antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties.
|
|
BP10798
|
OICR-9429
|
|
|
|
|
OICR-9429 is a potent antagonist of the interaction that WDR5 effect with peptide regions of MLL and Histone 3. It reduces the viability of acute myeloid leukemia cells in vitro.
|
|
BP10719
|
Olafertinib
|
|
|
|
|
CK-101 (RX-518) is a novel mutant-selective, irreversible, orally available EGFR inhibitor. It can overcome T790M-mediated resistance in NSCLC.
|
|
BP10800
|
Olmutinib
|
|
|
|
|
Olmutinib is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
|
|
BP10308
|
Olverembatinib
|
|
|
|
|
GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
|
